Pediatrix Medical Group, Inc. (NYSE:MD) Receives Consensus Rating of “Hold” from Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been assigned an average recommendation of “Hold” from the six research firms that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $22.50.

A number of equities analysts have recently commented on the stock. UBS Group increased their price objective on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Friday, March 27th. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Pediatrix Medical Group in a research note on Friday, February 20th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a research note on Friday, May 8th. Finally, Truist Financial raised their target price on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, April 13th.

Pediatrix Medical Group Trading Down 1.1%

Pediatrix Medical Group stock opened at $21.31 on Friday. The firm has a 50-day moving average of $21.79 and a 200-day moving average of $21.73. Pediatrix Medical Group has a one year low of $11.84 and a one year high of $24.99. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33. The company has a market cap of $1.75 billion, a price-to-earnings ratio of 10.34 and a beta of 0.70.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The company had revenue of $476.20 million during the quarter, compared to the consensus estimate of $465.83 million. During the same period in the prior year, the business posted $0.33 EPS. The company’s quarterly revenue was up 3.9% on a year-over-year basis. On average, equities analysts expect that Pediatrix Medical Group will post 2.08 earnings per share for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In related news, Director Shirley A. Weis sold 36,028 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Several hedge funds have recently bought and sold shares of the stock. Amundi lifted its position in Pediatrix Medical Group by 8.3% during the first quarter. Amundi now owns 15,744 shares of the company’s stock worth $337,000 after acquiring an additional 1,209 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Pediatrix Medical Group by 77.7% during the first quarter. EverSource Wealth Advisors LLC now owns 2,515 shares of the company’s stock worth $54,000 after purchasing an additional 1,100 shares during the period. Quantinno Capital Management LP increased its holdings in shares of Pediatrix Medical Group by 23.4% during the first quarter. Quantinno Capital Management LP now owns 22,928 shares of the company’s stock worth $490,000 after purchasing an additional 4,343 shares during the period. Lazard Asset Management LLC increased its holdings in shares of Pediatrix Medical Group by 22.1% during the first quarter. Lazard Asset Management LLC now owns 168,979 shares of the company’s stock worth $3,614,000 after purchasing an additional 30,621 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Pediatrix Medical Group by 12.9% during the first quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company’s stock worth $32,776,000 after purchasing an additional 174,600 shares during the period. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.